Screener / SEC EDGAR /CIK 0001521036 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Diagnostics

Lantheus Holdings, Inc. LNTH

Compare with peers Embed
FY2025 at a glance

Sales up 0.5%

XBRL, from each 10-K
RevenueStatements
$1.5B from $1.5B in FY2024
FY2016FY2025
Net incomeStatements
$233.6M from $312.4M in FY2024
FY2016FY2025
EPS (diluted)Statements
$3.41 from $4.36 in FY2024
FY2016FY2025
Operating marginStatements
20.2% from 29.8% in FY2024
FY2016FY2025
Total debtStatements
$569.4M from $566.3M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (42)
EPS (ttm)
4.02
Sales (ttm)
1.6B
Net income (ttm)
269.9M
Sales growth
+0.5%
EPS growth
-21.8%
Sales Q/Q
+1.5%
Free cash flow
-
Gross margin
61.3%
Oper. margin
18.6%
Net margin
17.3%
FCF margin
-
R&D / sales
11.5%
Dividend
-
Debt/Eq
0.42
Curr. ratio
3.25
Cash
683.6M
Op. cash flow (ttm)
409.5M
EBITDA
380.9M
EBITDA margin
24.7%
Net debt
-111.9M
Quick ratio
3.06
Interest cover
15.74
ROIC
12.0%
Goodwill / assets
10.8%
Oper. margin low 5y
-14.3%
Tax rate
25.6%
Stock pay / sales
5.6%
Shares out.
65.4M
Shares Y/Y
-4.5%
Book / share
20.73
Cash / share
10.45
Sales / share
23.89
Asset turnover
0.64
Inventory turns
9.27
Days sales out.
85
Sales 3Y CAGR
+18.1%
Sales 5Y CAGR
+35.4%
EPS 3Y CAGR
+104%
Employees
1,193
Sales / employee
1.3M

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 1.5B +19.9% a year Net income 233.6M +27.2% a year
FY2016 revenue 301.9M · Revenues, 0001628280-19-001574 FY2016 net income 26.8M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001628280-19-001574 301.9M FY2016 FY2017 revenue 331.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-20-002197 FY2017 net income 123.4M · NetIncomeLoss, 0001628280-20-002197 331.4M FY2017 FY2018 revenue 343.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-21-003336 FY2018 net income 40.5M · NetIncomeLoss, 0001628280-21-003336 343.4M FY2018 FY2019 revenue 347.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-22-003657 FY2019 net income 31.7M · NetIncomeLoss, 0001628280-22-003657 347.3M FY2019 FY2020 revenue 339.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-23-004698 FY2020 net income -13.5M · NetIncomeLoss, 0001628280-23-004698 339.4M FY2020 FY2021 revenue 425.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-24-006158 FY2021 net income -71.3M · NetIncomeLoss, 0001628280-24-006158 425.2M FY2021 FY2022 revenue 935.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-25-007970 FY2022 net income 28.1M · NetIncomeLoss, 0001628280-25-007970 935.1M FY2022 FY2023 revenue 1.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-073498 FY2023 net income 326.7M · NetIncomeLoss, 0001193125-26-073498 1.3B FY2023 FY2024 revenue 1.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-073498 FY2024 net income 312.4M · NetIncomeLoss, 0001193125-26-073498 1.5B FY2024 FY2025 revenue 1.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-073498 FY2025 net income 233.6M · NetIncomeLoss, 0001193125-26-073498 1.5B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +17.2% a year FY2016 $0.82 to FY2025 $3.41, 9 years
Book value per share +50.7% a year FY2017 $0.60 to FY2025 $15.92, 8 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $3.41$15.92-
Dec 31, 2024 $4.36$15.18-
Dec 31, 2023 $4.65$11.62$3.70
Dec 31, 2022 $0.40$6.33$0.31
Dec 31, 2021 -$1.06$6.88$0.80
Dec 31, 2020 -$0.25$9.50$0.30
Dec 31, 2019 $0.79$2.86$1.45
Dec 31, 2018 $1.03$1.80$1.04
Dec 31, 2017 $3.17$0.60$0.96
Dec 31, 2016 $0.82-$3.26$1.29
Dec 31, 2015 -$0.60-$7.58$0.35

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $900.0M
  • − All liabilities $1.1B
  • = Net current asset value -$237.6M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.1B
  • − Goodwill $239.5M
  • − Other intangible assets $722.8M
  • = Tangible book value $127.5M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

LNTH against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+0.5%135th of 155 · median +10.5%
Net margin
-4.1%15.3%
17.3%33rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
19.9%29th of 144 · median 9.2%
Debt / equity (less is better)
1.160.42
0.4228th of 108 · median 0.69
LNTH and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
LNTH Lantheus Holdings, Inc.$1.6B +0.5%61.3%17.3%19.9%-0.42
MMSI Merit Medical Systems Inc$1.6B +11.8%49.4%9.9%9.2%12.6%0.42
PEN Penumbra Inc$1.6B +17.5%68.0%10.1%9.9%12.8%-
INSM INSMED Inc$1.5B +66.7%84.4%-39.9%-83.4%-41.3%0.75
LIVN LivaNova PLC$1.5B +10.7%67.8%13.0%14.3%8.6%0.22
ADUS Addus HomeCare Corp$1.5B +23.2%32.3%7.4%9.4%9.6%0.02
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by region

From $935.1M of sales to $28.1M of profit FY2022

Revenue to Gross profit: $581.7MRevenue to Cost of revenue: $353.4MGross profit to Operating profit: $36.2MGross profit to Operating expenses: $545.5MOperating profit to Net profit: $28.1MOperating profit to Interest, tax, other: $8.1MOperating expenses to R&D: $311.7MOperating expenses to Sales, admin & other: $233.8M Revenue: $935.1M REVENUE $935.1M +120% Y/Y Gross profit: $581.7M · 62% margin GROSS PROFIT $581.7M 62% margin · +210% Y/Y Cost of revenue: $353.4M · 38% of revenue COST OF REVENUE $353.4M 38% of revenue Operating profit: $36.2M · 4% margin OPERATING PROFIT $36.2M 4% margin Operating expenses: $545.5M · 58% of revenue OPERATING EXPENSES $545.5M 58% of revenue Net profit: $28.1M · 3% margin NET PROFIT $28.1M 3% margin Interest, tax, other: $8.1M · 1% of revenue INTEREST, TAX, OTHER $8.1M 1% of revenue R&D: $311.7M · 33% of revenue R&D $311.7M 33% of revenue Sales, admin & other: $233.8M · 25% of revenue SALES, ADMIN & OTHER $233.8M 25% of revenue

From $1.3B of sales to $326.7M of profit FY2023

  • United States $1.3B
  • Rest of world $34.3M
Revenue to Gross profit: $709.5MRevenue to Cost of revenue: $586.9MGross profit to Operating profit: $364.6MGross profit to Operating expenses: $344.9MOperating profit to Net profit: $280.4MOperating profit to Tax: $84.3MOther income to Net profit: $46.3MOperating expenses to R&D: $77.7MOperating expenses to Sales, admin & other: $267.2M Revenue: $1.3B REVENUE $1.3B +39% Y/Y Gross profit: $709.5M · 55% margin GROSS PROFIT $709.5M 55% margin · +22% Y/Y Cost of revenue: $586.9M · 45% of revenue COST OF REVENUE $586.9M 45% of revenue Operating profit: $364.6M · 28% margin OPERATING PROFIT $364.6M 28% margin · +907% Y/Y Other income: $46.3M · 4% of revenue OTHER INCOME $46.3M 4% of revenue Operating expenses: $344.9M · 27% of revenue OPERATING EXPENSES $344.9M 27% of revenue Net profit: $326.7M · 25% margin NET PROFIT $326.7M 25% margin · +1064% Y/Y Tax: $84.3M · 7% of revenue TAX $84.3M 7% of revenue R&D: $77.7M · 6% of revenue R&D $77.7M 6% of revenue Sales, admin & other: $267.2M · 21% of revenue SALES, ADMIN & OTHER $267.2M 21% of revenue

From $1.5B of sales to $312.4M of profit FY2024

  • United States $1.5B
  • Rest of world $49.2M
Revenue to Gross profit: $988.3MRevenue to Cost of revenue: $545.6MGross profit to Operating profit: $457.0MGross profit to Operating expenses: $531.3MOperating profit to Net profit: $312.4MOperating profit to Tax & other: $144.5MOperating expenses to R&D: $168.1MOperating expenses to Sales, admin & other: $363.2M Revenue: $1.5B REVENUE $1.5B +18% Y/Y Gross profit: $988.3M · 64% margin GROSS PROFIT $988.3M 64% margin · +39% Y/Y Cost of revenue: $545.6M · 36% of revenue COST OF REVENUE $545.6M 36% of revenue Operating profit: $457.0M · 30% margin OPERATING PROFIT $457.0M 30% margin · +25% Y/Y Operating expenses: $531.3M · 35% of revenue OPERATING EXPENSES $531.3M 35% of revenue Net profit: $312.4M · 20% margin NET PROFIT $312.4M 20% margin · −4% Y/Y Tax & other: $144.5M · 9% of revenue TAX & OTHER $144.5M 9% of revenue R&D: $168.1M · 11% of revenue R&D $168.1M 11% of revenue Sales, admin & other: $363.2M · 24% of revenue SALES, ADMIN & OTHER $363.2M 24% of revenue

From $1.5B of sales to $233.6M of profit FY2025

  • United States $1.5B
  • Rest of world $82.7M
Revenue to Gross profit: $942.0MRevenue to Cost of revenue: $599.7MGross profit to Operating profit: $310.8MGross profit to Operating expenses: $631.1MOperating profit to Net profit: $233.6MOperating profit to Tax & other: $77.3MOperating expenses to R&D: $177.3MOperating expenses to Sales, admin & other: $453.8M Revenue: $1.5B REVENUE $1.5B +1% Y/Y Gross profit: $942.0M · 61% margin GROSS PROFIT $942.0M 61% margin · −5% Y/Y Cost of revenue: $599.7M · 39% of revenue COST OF REVENUE $599.7M 39% of revenue Operating profit: $310.8M · 20% margin OPERATING PROFIT $310.8M 20% margin · −32% Y/Y Operating expenses: $631.1M · 41% of revenue OPERATING EXPENSES $631.1M 41% of revenue Net profit: $233.6M · 15% margin NET PROFIT $233.6M 15% margin · −25% Y/Y Tax & other: $77.3M · 5% of revenue TAX & OTHER $77.3M 5% of revenue R&D: $177.3M · 12% of revenue R&D $177.3M 12% of revenue Sales, admin & other: $453.8M · 29% of revenue SALES, ADMIN & OTHER $453.8M 29% of revenue

Where each $100 of sales went

FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 21.4% FY2020: -2.6% net income ÷ equity
Net margin 15.2% FY2020: -4.0% profit per $ of sales: 233.6M ÷ 1.5B
Asset turnover 0.69× FY2020: 0.39× sales per $ of assets: 1.5B ÷ 2.2B
Leverage 2.04× FY2020: 1.69× assets per $ of equity: 2.2B ÷ 1.1B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    17.3% vs 6.8%
  • Gross margin up over 5 years
    40.9% → 61.1%
  • Return on equity above 15%
    19.9%
  • A profit in 8 of 10 years
Net margin, FY2016 to FY2025: 8.9% to 15.2%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 15.7× interest expense
  • Debt smaller than equity
    Debt / equity 0.42 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 3.25
  • More cash than debt
    Net cash $111.9M
Debt / equity at each year end, FY2016 to FY2025: 11.51 to 0.52

Cash and shareholders

  • Free cash flow positive in every one of 8 years
    $259.9M last year
  • Share count up over 5 years
    +26.4%
  • Cash from operations above net income
    $390.1M vs $233.6M
Free cash flow, FY2016 to FY2025: 42.2M to 259.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$- of principal due

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

LNTH's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.5B
FY2016: 301.9MFY2017: 331.4MFY2018: 343.4MFY2019: 347.3MFY2020: 339.4MFY2021: 425.2MFY2022: 935.1MFY2023: 1.3BFY2024: 1.5BFY2025: 1.5B FY2017FY2019FY2021FY2023FY2025
Net income233.6M
FY2016: 26.8MFY2017: 123.4MFY2018: 40.5MFY2019: 31.7MFY2020: -13.5MFY2021: -71.3MFY2022: 28.1MFY2023: 326.7MFY2024: 312.4MFY2025: 233.6M FY2017FY2019FY2021FY2023FY2025
Free cash flow259.9M
FY2016: 42.2MFY2017: 37.2MFY2018: 41.1MFY2019: 58.3MFY2020: 16.4MFY2021: 53.9MFY2022: 21.8MFY2023: 259.9MFY2024: -FY2025: - FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay209.4M
FY2016: 39.7MFY2017: 31.3MFY2018: 32.3MFY2019: 45.8MFY2020: 2.3MFY2021: 38.0MFY2022: -7.5MFY2023: 209.4MFY2024: -FY2025: - FY2017FY2019FY2021FY2023FY2025
EPS (diluted)3.41
FY2016: 0.82FY2017: 3.17FY2018: 1.03FY2019: 0.79FY2020: -0.25FY2021: -1.06FY2022: 0.40FY2023: 4.65FY2024: 4.36FY2025: 3.41 FY2017FY2019FY2021FY2023FY2025
Diluted shares68.4M
FY2016: 32.7MFY2017: 38.9MFY2018: 39.5MFY2019: 40.1MFY2020: 54.1MFY2021: 67.5MFY2022: 70.7MFY2023: 70.2MFY2024: 71.7MFY2025: 68.4M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
PYLARIFY 989.1M64.2% -6.5%
Total radiopharmaceutical oncology 989.1M64.2% -6.5%
DEFINITY 330.2M21.4% +3.9%
TechneLite 86.8M5.6% -9.1%
Strategic partnerships and other revenue 59.4M3.9% +55.5%
Neuraceq 51.4M3.3% -
License and royalty revenues 34.0M2.2% +273%
Other precision diagnostics 24.6M1.6% +1.6%
Other radiopharmaceutical oncology 00.0% -100%

10-K 0001193125-26-073498, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 1.5B94.6% -1.7%
Rest of world 82.7M5.4% +68.1%

10-K 0001193125-26-073498, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue301.9M331.4M343.4M347.3M339.4M425.2M935.1M1.3B1.5B1.5B
Cost of revenue164.1M169.2M168.5M172.5M200.6M237.5M353.4M586.9M545.6M599.7M
Gross profit137.8M162.1M174.9M174.8M138.8M187.7M581.7M709.5M988.3M942.0M
R&D12.2M18.1M17.1M20.0M32.8M45.0M311.7M77.7M168.1M177.3M
SG&A38.8M49.8M50.2M61.2M69.3M150.4M133.6M125.5M193.7M275.1M
Operating income56.6M51.9M64.5M51.7M-4.2M-60.8M36.2M364.6M457.0M310.8M
Interest expense26.6M18.4M17.4M13.6M9.5M7.8M7.2M20.0M19.7M19.7M
Pretax income28.3M39.6M49.5M28.6M-11.5M-75.0M26.7M410.9M431.0M313.8M
Income tax1.5M-83.7M9.0M-3.0M2.0M-3.8M-1.3M84.3M118.5M80.2M
Net income26.8M123.4M40.5M31.7M-13.5M-71.3M28.1M326.7M312.4M233.6M
EPS (diluted)0.823.171.030.79-0.25-1.060.404.654.363.41
Diluted shares32.7M38.9M39.5M40.1M54.1M67.5M70.7M70.2M71.7M68.4M
Depreciation & amortization17.3M18.2M12.8M12.1M23.3M42.3M47.9M60.0M64.6M70.1M
EBITDA73.9M70.0M77.3M63.7M19.1M-18.5M84.1M424.7M521.6M380.9M
Gross margin45.6%48.9%50.9%50.3%40.9%44.1%62.2%54.7%64.4%61.1%
Operating margin18.7%15.6%18.8%14.9%-1.2%-14.3%3.9%28.1%29.8%20.2%
Net margin8.9%37.2%11.8%9.1%-4.0%-16.8%3.0%25.2%20.4%15.2%
Revenue growth+2.9%+9.8%+3.6%+1.2%-2.3%+25.3%+120%+38.6%+18.3%+0.5%
EPS growth-+287%-67.5%-23.3%to a loss--+1062%-6.2%-21.8%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow49.6M54.8M61.2M80.4M16.4M53.9M281.8M305.3M544.8M390.1M
Capital spending7.4M17.5M20.1M22.1M00260.0M45.3M--
Free cash flow42.2M37.2M41.1M58.3M16.4M53.9M21.8M259.9M--
Stock-based pay (added back)2.5M5.9M8.7M12.5M14.1M15.9M29.3M50.5M76.4M85.6M
Free cash flow after stock pay39.7M31.3M32.3M45.8M2.3M38.0M-7.5M209.4M--
Buybacks----0075.0M0100.0M300.0M
Debt raised0274.3M0199.5M00557.8M00-
Debt repaid78.7M286.7M2.9M275.4M15.5M43.3M175.4M717K318K1.1M
Investing cash flow3.3M-16.3M-19.1M-22.1M-4.9M3.7M-276.5M5.9M-226.0M-627.2M
Financing cash flow-30.2M-13.4M-4.7M-78.9M-21.9M-39.3M311.7M-13.1M-118.5M-316.6M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)2.5M5.9M8.7M12.5M14.1M15.9M29.3M50.5M76.4M85.6M
Stock-based pay / revenue0.8%1.8%2.5%3.6%4.1%3.7%3.1%3.9%5.0%5.6%
Operating lease cost---223K1.5M2.3M1.8M4.6M6.4M6.1M
Operating lease cash paid---230K1.2M2.1M2.4M3.5M4.5M2.3M
Finance lease principal paid---190K207K339K384K504K318K1.1M
Right-of-use assets---935K18.4M8.8M19.0M45.3M36.1M31.0M
Operating lease liabilities---1.0M18.7M18.1M27.6M56.4M55.1M53.8M
Finance lease liabilities---329K495K691K585K1.4M1.6M1.2M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LNTH/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.